Everence Capital Management Inc. grew its holdings in Emergent Biosolutions Inc (NYSE:EBS) by 64.1% during the 1st quarter, Holdings Channel reports. The firm owned 6,500 shares of the biopharmaceutical company’s stock after buying an additional 2,540 shares during the period. Everence Capital Management Inc.’s holdings in Emergent Biosolutions were worth $328,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in Emergent Biosolutions by 22.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 26,779 shares of the biopharmaceutical company’s stock worth $1,763,000 after purchasing an additional 4,980 shares in the last quarter. Neuberger Berman Group LLC bought a new position in Emergent Biosolutions during the 3rd quarter valued at about $22,064,000. Morgan Stanley lifted its stake in Emergent Biosolutions by 44.9% during the 3rd quarter. Morgan Stanley now owns 254,168 shares of the biopharmaceutical company’s stock valued at $16,731,000 after acquiring an additional 78,700 shares during the period. Federated Investors Inc. PA lifted its stake in Emergent Biosolutions by 30.3% during the 3rd quarter. Federated Investors Inc. PA now owns 219,460 shares of the biopharmaceutical company’s stock valued at $14,446,000 after acquiring an additional 50,980 shares during the period. Finally, State of Alaska Department of Revenue lifted its stake in Emergent Biosolutions by 5.2% during the 4th quarter. State of Alaska Department of Revenue now owns 14,989 shares of the biopharmaceutical company’s stock valued at $888,000 after acquiring an additional 737 shares during the period. 83.77% of the stock is currently owned by institutional investors and hedge funds.
In other news, CEO Daniel Abdun-Nabi sold 14,565 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $58.11, for a total value of $846,372.15. Following the transaction, the chief executive officer now owns 142,617 shares in the company, valued at approximately $8,287,473.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Adam Havey sold 2,430 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $56.93, for a total transaction of $138,339.90. Following the completion of the transaction, the executive vice president now owns 32,240 shares in the company, valued at approximately $1,835,423.20. The disclosure for this sale can be found here. Insiders sold a total of 58,132 shares of company stock worth $3,411,113 in the last quarter. Company insiders own 14.10% of the company’s stock.
Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.13 by ($0.26). Emergent Biosolutions had a return on equity of 11.73% and a net margin of 4.88%. The business had revenue of $190.60 million during the quarter, compared to the consensus estimate of $201.36 million. During the same quarter last year, the company earned ($0.03) EPS. Emergent Biosolutions’s revenue for the quarter was up 61.8% on a year-over-year basis. As a group, analysts expect that Emergent Biosolutions Inc will post 3.06 EPS for the current year.
EBS has been the topic of several research analyst reports. Zacks Investment Research cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Monday, April 8th. Cantor Fitzgerald restated a “buy” rating and set a $75.00 target price on shares of Emergent Biosolutions in a research note on Thursday, May 2nd. Wells Fargo & Co set a $68.00 target price on shares of Emergent Biosolutions and gave the company a “hold” rating in a research note on Tuesday, April 2nd. Chardan Capital set a $71.00 target price on shares of Emergent Biosolutions and gave the company a “buy” rating in a research note on Friday, February 22nd. Finally, ValuEngine cut shares of Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Wednesday, March 20th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $68.86.
ILLEGAL ACTIVITY NOTICE: “Emergent Biosolutions Inc (EBS) Stake Boosted by Everence Capital Management Inc.” was originally reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/18/emergent-biosolutions-inc-ebs-stake-boosted-by-everence-capital-management-inc.html.
About Emergent Biosolutions
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.
Featured Story: What are catch-up contributions?
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.